关于 Tafamidis Meglumine API

Product
  • CAS 编号

    951395-08-7

  • API 技术

    合成

  • 剂型

    软胶囊

  • Dr Reddy's 开发状态

    可用的

  • 可用的法规申报文件

    巴西 DMF, USDMF

Mechanism of Action

Tafamidis Meglumine is a drug used to treat transthyretin (TTR) amyloidosis, a rare genetic disease characterized by the buildup of abnormal proteins in various tissues and organs, including the heart, peripheral nerves, and eyes.

The mechanism of action of Tafamidis Meglumine is based on its ability to stabilize the TTR tetramer, which is the native form of the protein. Tafamidis Meglumine binds to the TTR protein and prevents it from undergoing a conformational change that would normally lead to its aggregation and formation of amyloid fibrils. By stabilizing the TTR tetramer, Tafamidis Meglumine slows down the progression of TTR amyloidosis and helps to preserve the function of affected tissues and organs.

In addition, Tafamidis Meglumine has been shown to have an anti-inflammatory effect, which may also contribute to its therapeutic effects in TTR amyloidosis.

Indication

Tafamidis Meglumine is a medication used to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a type of heart disease caused by buildup of amyloid deposits in the heart. It works by stabilizing the transthyretin protein, which helps to prevent the formation of amyloid deposits and slow the progression of heart damage.

Tafamidis Meglumine is indicated for the treatment of transthyretin amyloid cardiomyopathy in adult patients with stage F2 or F3 cardiac symptoms (based on the New York Heart Association [NYHA] functional classification).

It is important to note that Tafamidis Meglumine is not a cure for transthyretin amyloid cardiomyopathy, but it can help to slow the progression of the disease and improve symptoms in some patients.

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Country *
Select Product *
Select Regulatory Requirements
Select Purpose

Related APIs

Atorvastatin Calcium (Form 1)(阿托伐他汀钙,1 晶型)

Cardiology(心血管)

arrow

Edoxoban (甲苯磺酸依度沙班一水合物)

Cardiology(心血管)

arrow

Ticagrelor(替格瑞洛)

Cardiology(心血管)

arrow

Rivaroxaban(利伐沙班)

Cardiology(心血管)

arrow

Ramipril(雷米普利)

Cardiology(心血管)

arrow

Clopidogrel Bisulfate (For 1)(硫酸氢氯吡格雷,1 晶型)

Cardiology(心血管)

arrow

Clopidogrel Bisulfate (Form 2)(硫酸氢氯吡格雷,2 晶型)

Cardiology(心血管)

arrow

Ezetimibe(依折麦布)

Cardiology(心血管)

arrow

Fondaparinux Sodium(磺达肝癸钠)

Cardiology(心血管)

arrow

Lacidipine(拉西地平)

Cardiology(心血管)

arrow

Amlodipine Besylate(苯磺酸氨氯地平)

Cardiology(心血管)

arrow

Sacubitril ‑ Valsartan(沙库巴曲缬沙坦)

Cardiology(心血管)

arrow

Apixaban(阿哌沙班)

Cardiology(心血管)

arrow

Bempedoic Acid(‌贝派地酸)

Cardiology(心血管)

arrow

Valsartan(缬沙坦)

Cardiology(心血管)

arrow

Metoprolol Succinate(琥珀酸美托洛尔)

Cardiology(心血管)

arrow

Tafamidis Free Acid(氯苯唑酸游离酸)

Cardiology(心血管)

arrow

Dabigatran Granules

Cardiology(心血管)

arrow

Treprostinil(曲前列尼尔)

Cardiology(心血管)

arrow

Acoramidis(阿可拉米地)

Cardiology(心血管)

arrow

Doxazosin Mesylate(甲磺酸多沙唑嗪)

Cardiology(心血管)

arrow

免责声明

本網站上的任何信息,包括對任何產品或服務的任何提及,均不構成銷售要約或被解釋為代表銷售要約。受有效專利保護的產品不得提供或供應用於商業用途。但是,在某些情況下,雷迪博士可自行決定並根據當地法律要求,在存在此類監管豁免的任何地方,提供此類產品的研究數量,以根據《印度專利法》第 107A 條(Bolar 豁免)進行監管提交。購買者應對其各自市場的產品或服務(包括專利情況)進行獨立評估,並對所有與專利相關的責任負責。 Dr. Reddy's 不承擔任何明示或暗示的保證,包括但不限於適銷性、適用於特定用途和非侵權的保證。

Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patents Act (Bolar Exemption) and not for commercial sale.
氯苯唑酸葡甲胺 API制造商和供应商| CAS 951395-08-7 - Dr. Reddy's